Patricia K Nguyen1, Evgenios Neofytou2, June-Wha Rhee2, Joseph C Wu3. 1. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California2Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California3Veterans Affairs Palo Alto Health Care System, Palo Alto, California. 2. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California2Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California. 3. Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California2Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California4Department of Radiology, Stanford University School of Medicine, Stanford, California.
Abstract
Importance: Although progress continues to be made in the field of stem cell regenerative medicine for the treatment of cardiovascular disease, significant barriers to clinical implementation still exist. Objectives: To summarize the current barriers to the clinical implementation of stem cell therapy in patients with cardiovascular disease and to discuss potential strategies to overcome them. Evidence Review: Information for this review was obtained through a search of PubMed and the Cochrane database for English-language studies published between January 1, 2000, and July 25, 2016. Ten randomized clinical trials and 8 systematic reviews were included. Findings: One of the major clinical barriers facing the routine implementation of stem cell therapy in patients with cardiovascular disease is the limited and inconsistent benefit observed thus far. Reasons for this finding are unclear but may be owing to poor cell retention and survival, as suggested by numerous preclinical studies and a small number of human studies incorporating imaging to determine cell fate. Additional studies in humans using imaging to determine cell fate are needed to understand how these factors contribute to the limited efficacy of stem cell therapy. Treatment strategies to address poor cell retention and survival are under investigation and include the following: coadministration of immunosuppressive and prosurvival agents, delivery of cardioprotective factors packaged in exosomes rather than the cells themselves, and use of tissue-engineering strategies to provide structural support for cells. If larger grafts are achieved using these strategies, it will be imperative to carefully monitor for the potential risks of tumorigenicity, immunogenicity, and arrhythmogenicity. Conclusions and Relevance: Despite important achievements to date, stem cell therapy is not yet ready for routine clinical implementation. Significant research is still needed to address the clinical barriers outlined herein before the next wave of large clinical trials is under way.
Importance: Although progress continues to be made in the field of stem cell regenerative medicine for the treatment of cardiovascular disease, significant barriers to clinical implementation still exist. Objectives: To summarize the current barriers to the clinical implementation of stem cell therapy in patients with cardiovascular disease and to discuss potential strategies to overcome them. Evidence Review: Information for this review was obtained through a search of PubMed and the Cochrane database for English-language studies published between January 1, 2000, and July 25, 2016. Ten randomized clinical trials and 8 systematic reviews were included. Findings: One of the major clinical barriers facing the routine implementation of stem cell therapy in patients with cardiovascular disease is the limited and inconsistent benefit observed thus far. Reasons for this finding are unclear but may be owing to poor cell retention and survival, as suggested by numerous preclinical studies and a small number of human studies incorporating imaging to determine cell fate. Additional studies in humans using imaging to determine cell fate are needed to understand how these factors contribute to the limited efficacy of stem cell therapy. Treatment strategies to address poor cell retention and survival are under investigation and include the following: coadministration of immunosuppressive and prosurvival agents, delivery of cardioprotective factors packaged in exosomes rather than the cells themselves, and use of tissue-engineering strategies to provide structural support for cells. If larger grafts are achieved using these strategies, it will be imperative to carefully monitor for the potential risks of tumorigenicity, immunogenicity, and arrhythmogenicity. Conclusions and Relevance: Despite important achievements to date, stem cell therapy is not yet ready for routine clinical implementation. Significant research is still needed to address the clinical barriers outlined herein before the next wave of large clinical trials is under way.
Authors: Dongming Hou; Eyas Al-Shaykh Youssef; Todd J Brinton; Ping Zhang; Pamela Rogers; Erik T Price; Alan C Yeung; Brian H Johnstone; Paul G Yock; Keith L March Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Bojan Vrtovec; Gregor Poglajen; Luka Lezaic; Matjaz Sever; Aljaz Socan; Dragoslav Domanovic; Peter Cernelc; Guillermo Torre-Amione; François Haddad; Joseph C Wu Journal: Circulation Date: 2013-09-10 Impact factor: 29.690
Authors: Sonya B Seif-Naraghi; Jennifer M Singelyn; Michael A Salvatore; Kent G Osborn; Jean J Wang; Unatti Sampat; Oi Ling Kwan; G Monet Strachan; Jonathan Wong; Pamela J Schup-Magoffin; Rebecca L Braden; Kendra Bartels; Jessica A DeQuach; Mark Preul; Adam M Kinsey; Anthony N DeMaria; Nabil Dib; Karen L Christman Journal: Sci Transl Med Date: 2013-02-20 Impact factor: 17.956
Authors: Rutger-Jan Swijnenburg; Sonja Schrepfer; Johannes A Govaert; Feng Cao; Katie Ransohoff; Ahmad Y Sheikh; Munif Haddad; Andrew J Connolly; Mark M Davis; Robert C Robbins; Joseph C Wu Journal: Proc Natl Acad Sci U S A Date: 2008-08-26 Impact factor: 11.205
Authors: Zhouguang Wang; Daniel W Long; Yan Huang; William C W Chen; Kang Kim; Yadong Wang Journal: Acta Biomater Date: 2019-01-30 Impact factor: 8.947
Authors: Andrew S Lee; Mohammed Inayathullah; Maarten A Lijkwan; Xin Zhao; Wenchao Sun; Sujin Park; Wan Xing Hong; Mansi B Parekh; Andrey V Malkovskiy; Edward Lau; Xulei Qin; Venkata Raveendra Pothineni; Verónica Sanchez-Freire; Wendy Y Zhang; Nigel G Kooreman; Antje D Ebert; Charles K F Chan; Patricia K Nguyen; Jayakumar Rajadas; Joseph C Wu Journal: Nat Biomed Eng Date: 2018-02-06 Impact factor: 25.671